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NAC is a conserved protein biogenesis
factor. Shen et al. demonstrate that NAC
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aggregation and toxicity of human
disease-related polyglutamine-expanded
proteins. They identify the positively
charged domain of bNAC as the critical
chaperone domain and show that NAC
also acts independent of its ribosome
association.
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The nascent polypeptide-associated complex (NAC)
is a conserved ribosome-associated protein biogen-
esis factor. Whether NAC exerts chaperone activity
and whether this function is restricted to de novo
protein synthesis is unknown. Here, we demonstrate
that NAC directly exerts chaperone activity toward
structurally diverse model substrates including poly-
glutamine (PolyQ) proteins, firefly luciferase, and
Ab40. Strikingly, we identified the positively charged
ribosome-binding domain in the N terminus of the
bNAC subunit (N-bNAC) as a major chaperone entity
of NAC. N-bNAC by itself suppressed aggregation of
PolyQ-expanded proteins in vitro, and the positive
charge of this domain was critical for this activity.
Moreover, we found that NAC also exerts a ribo-
some-independent chaperone function in vivo.
Consistently, we found that a substantial fraction of
NAC is non-ribosomal bound in higher eukaryotes.
In sum, NAC is a potent suppressor of aggregation
and proteotoxicity of mutant PolyQ-expanded
proteins associated with human diseases like Hun-
tington’s disease and spinocerebellar ataxias.
INTRODUCTION
A multifaceted chaperone network guards the integrity of the
cellular proteome. This network comprises various conserved
families of molecular chaperones operating in all cellular sub-
compartments to promote the folding and function of their
protein substrates and counteract proteotoxicity provoked by
protein misfolding and aggregation (Kim et al., 2013). A subset
of molecular chaperones is specialized for de novo proteinMolecular Cell 74, 729–741
This is an open access article under the CC BY-Nfolding, including the ribosome-associated complex (RAC) in eu-
karyotes or trigger factor in bacteria. These systems directly bind
to translating ribosomes near the peptide exit tunnel to engage
their substrates in a co-translational manner. Installed at the
ribosome, they are enabled to assist protein folding at the
earliest possible time when nascent chains are just reaching
the cytoplasm. These chaperones thus lay the groundwork for
the maintenance of protein homeostasis in the cell (Pechmann
et al., 2013; Preissler and Deuerling, 2012).
Amajor factor in eukaryotes that quantitatively associates with
translating ribosomes near the peptide exit site is the ubiquitous
nascent polypeptide-associated complex (NAC) (Wiedmann
et al., 1994). It consists of two different subunits, aNAC and
bNAC, that dimerize when their homologous NAC domains
form a semi-b-barrel core (Liu et al., 2010; Wang et al., 2010).
NAC is an abundant complex expressed at least equimolar
relative to ribosomes; thus, most translating ribosomes likely
associate with NAC (del Alamo et al., 2011; Raue et al., 2007).
Essential for ribosome binding is an 40 aa domain found
specifically in the N terminus of the bNAC subunit (herein
N-bNAC). N-bNAC is highly conserved and exhibits a character-
istic positive net charge. Deletion of either the first N-terminal 11
amino acids or mutation of a conserved positively charged
central motif (RRKxxKK) abolishes ribosome binding in yeast,
suggesting that this domain mediates the main ribosomal con-
tact of NAC (Pech et al., 2010; Wegrzyn et al., 2006).
Because of its localization at the ribosomal tunnel exit, a
proposed function of NAC is to act as a co-translational molec-
ular chaperone similar to the ATP-independent trigger factor in
bacteria. However, only indirect evidence supports this
assumption, and mechanistic details of the proposed chap-
erone activity are entirely unknown (Duttler et al., 2013;
Kirstein-Miles et al., 2013; Ott et al., 2015; Wang et al., 2013).
Crosslinking data suggest that both NAC subunits can interact
with protein clients, but the particular substrate binding site(s)
of a- and bNAC and the substrate binding specificity are un-
known (Martin et al., 2018; Wang et al., 1995). Further, whether, May 16, 2019 ª 2019 The Authors. Published by Elsevier Inc. 729
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. NAC Suppresses Aggregation of Diverse PolyQ Proteins
(A) Fluorescencemicroscope images of PolyQ35::YFPC. elegansworms overexpressing NAC (FLAG-tagged a- and bNAC) in muscle cells. Images were taken at
day 3 of adulthood. Scalebar, 500 mm inwhole body images and 50 mm in images showing the head region. PolyQ35::YFP aggregates and cell nuclei are indicated
by white and blue arrowheads, respectively. ev, empty vector.
(legend continued on next page)
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NAC has a function aside from its co-translational ribosomal
role is unknown.
Here, we conducted a series of in vitro and in vivo experi-
ments to explore the potential chaperone function of NAC in
greater detail. We found that NAC directly exerts chaperone
activity as a holdase toward a set of structurally and physico-
chemically diverse model substrates. NAC effectively
suppresses aggregation of disease-related polyglutamine-
expanded (polyQ) proteins and amyloid-b 40 (Ab40) peptides,
as well as denatured firefly luciferase, independent from its
ribosome association. Specifically, our data reveal that the
ribosome-binding domain N-bNAC represents a central chap-
erone domain of NAC. Moreover, we found that NAC enhances
organismal fitness of PolyQ-expressing C. elegans animals and
prevents proteostasis collapse in neurons expressing PolyQ-
expanded Huntingtin. These data suggest that NAC is a
chaperone that acts as a potent modifier of age-related
proteinopathies.
RESULTS
NAC Suppresses Aggregation of Diverse PolyQ Proteins
NAC is a major ribosome-binding factor interacting broadly with
nascent chains (del Alamo et al., 2011). However, its assumed
chaperone function is poorly investigated. A previous study in
C. elegans showed that depletion of NAC leads to increased ag-
gregation of a model PolyQ protein (Kirstein-Miles et al., 2013).
Although loss of NAC causes pleiotropic defects in C. elegans
(Gamerdinger et al., 2015), this finding raises the possibility
that NAC directly exerts a chaperone function on aggregation-
prone proteins. In this case, overexpression of NAC should pre-
vent aggregation of PolyQ proteins in vivo. Therefore, we used a
C. elegans strain expressing 35 consecutive glutamine residues
fused to YFP (PolyQ35::YFP) in body-wall muscle cells. This
PolyQ length is close to the aggregation threshold in
C. elegans muscle cells, leading to progressive, age-dependent
aggregation starting at day 2 of adulthood (Morley et al., 2002).
We generated transgenic animals that overexpress FLAG-
tagged a- and bNAC under the control of the muscle-specific
myo-3 promoter. PolyQ aggregation was assessed at day 3 of
adulthood by fluorescence microscopy as well as semi-dena-
turing detergent agarose gel electrophoresis (SDD-AGE), which
detects high-molecular weight oligomeric PolyQ species (Half-
mann and Lindquist, 2008). The overexpression of NAC did not
alter the overall morphology of C. elegans and expression levels
of PolyQ35::YFP (Figure 1A, whole body images). However, we
found that overexpression of NAC effectively suppressed
PolyQ35::YFP aggregation in worms. This is evident by magnifi-(B) PolyQ35::YFP aggregation in animals as in (A) was further assessed by semi-d
levels of SDS-soluble PolyQ35::YFP and FLAG-tagged NAC subunits were asse
control.
(C) Filter trap aggregation assay of PolyQ51 peptide incubated with 53 molar e
cleavage of the GST tag using the TEV protease. SDS-insoluble aggregates wer
(D) Quantification of SDS-insoluble PolyQ51 aggregates obtained in filter trap fro
(E) Filter trap aggregation assay ofmutant Huntingtin (mHttQ51) incubated with 53
GST-mHttQ51 was initiated by cleavage of the GST tag using the TEV protease.
(F) Quantification of SDS-insoluble mHttQ51 aggregates obtained in filter trap fro
See also Figure S1.cation of the head regions showing diffuse PolyQ35::YFP and
less punctate PolyQ35::YFP structures when NAC was overex-
pressed (Figure 1A, head region images). Consistent with the
fluorescence microscopy analysis, we found less insoluble
high molecular weight aggregate species in NAC-overexpress-
ing worms by SDD-AGE analysis (Figures 1B and S1A). These
data indicate that NAC is a modifier of PolyQ aggregation. To
directly test the potential chaperone function of NAC, we
employed a peptide composed of 51 consecutive glutamines
(PolyQ51) as a model substrate in a well-established in vitro
aggregation assay. We initiated aggregation of PolyQ51 by
cleaving a solubilizing GST tag with TEV protease and detected
aggregates over time using a filter trap assay. Addition of purified
human NAC strongly delayed the accumulation of PolyQ51
aggregates (Figures 1C and 1D), suggesting that NAC directly
acts on the polyglutamine stretch and slows the rate of
aggregation.
The aggregation suppression effect of NAC on the pure PolyQ
substrate predicts that NACmay also inhibit aggregation of path-
ogenic proteins harboring an extended PolyQ tract. Thus, we
investigated whether NAC prevents aggregation of mutant Hun-
tingtin exon 1, the causative agent in the human neurodegener-
ative disorder Huntington’s disease (Labbadia and Morimoto,
2013). Using the same in vitro filter trap aggregation assay, we
found that human NAC effectively suppressed aggregation of
mutant Huntingtin exon 1 containing a pathogenic stretch of 51
glutamines (mHttQ51), whereas a molar equivalent ovalbumin
control showed little effect (Figures 1E and 1F). Aggregation sup-
pression of mHttQ51 by NACwas concentration dependent (Fig-
ure S1B) and was also observed, albeit to a lesser extent, with
the C. elegans form of NAC (Figure S1C). Moreover, we found
that NAC did not disaggregate preformed mHttQ51 aggregates
in vitro (Figure S1D), suggesting that NAC exhibits a holdase
function on early aggregation species to prevent further oligo-
merization, similar to the apical domain of the chaperonin TRiC
(Tam et al., 2006).
A second pathogenic PolyQ substrate tested was full-length
ataxin-3 harboring a stretch of 78 glutamines (AtxQ78), which
causes spinocerebellar ataxia-3 in humans (Matos et al., 2011).
Importantly, this protein shares no homology with Huntingtin
exon 1 aside from the mutant expansion of a PolyQ repeat and
aggregates via a separate kinetic mechanism (Saunders and
Bottomley, 2009; Scarff et al., 2015). AtxQ78 exhibits lower
aggregation propensity compared to PolyQ51 and mHttQ51,
circumventing the requirement of a solubilizing tag. To assess
whether NAC also affects AtxQ78 aggregation, we incubated
the AtxQ78 substrate in the presence or absence of purified hu-
man NAC at 37C and assessed aggregation by a filter trapenaturing agarose gel electrophoresis (SDD-AGE) immunoblot analysis. Total
ssed by denaturing SDS-PAGE immunoblot analysis. Actin served as loading
xcess of human NAC in vitro. Aggregation of GST-PolyQ51 was initiated by
e detected with an S-tag antibody.
m (C). Data are representative of at least 3 independent biological replicates.
molar excess of humanNACor ovalbumin control (Ova) in vitro. Aggregation of
SDS-insoluble aggregates were detected with an S-tag antibody.
m (E). Data are representative of at least 3 independent biological replicates.
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Figure 2. NAC Suppresses Aggregation of
Mutant Ataxin-3
(A) Filter trap aggregation assay of full-length Ataxin-3
containing a stretch of 78 glutamines (AtxQ78) incu-
bated with 13 molar excess of NAC at 37C for the
indicated time. SDS-insoluble aggregates were
detected with an anti-His antibody.
(B) Quantification of SDS-insoluble AtxQ78 aggre-
gates obtained in filter trap from (A). Data are repre-
sentative of at least 3 independent biological
replicates.
(C) NAC and AtxQ78 were incubated in a 1:1 molar
ratio and crosslinked using the homobifunctional
crosslinker BS3. The schematic shows all intermolec-
ular BS3 crosslinks identified by MS analysis of NAC-
AtxQ78 complexes excised from the gel shown in
Figure S2C.
See also FigureS2 and Table S1.assay. Similar to the effect on PolyQ51 and mHttQ51, addition of
human NAC delayed the aggregation of AtxQ78 (Figures 2A and
2B). TheC. elegansNAC homolog also prevented AtxQ78 aggre-
gation but was slightly less effective than the human isoform
(Figure S2A).
Next, we mapped the PolyQ substrate binding site in NAC
using a crosslinking and mass spectrometry (MS) approach.
We used full-length AtxQ78 as our PolyQ model substrate for
crosslinking to NAC for several reasons. First, AtxQ78 exhibits
lower aggregation propensity than mHttQ51 or PolyQ51, allow-
ing for crosslinking without concern for increasing the rate of
the aggregation reaction. Second, the AtxQ78 construct does
not require use of a solubilizing tag, avoiding the presence of
additional factors during the crosslinking reaction. Third, while
NAC may directly interact with the PolyQ region, glutamine
does not contain any optimal functional groups for chemical
crosslinking. However, AtxQ78 has many lysine residues,
including several directly up-stream of the polyglutamine re-
gion, facilitating chemical crosslinking with amine-reactive
crosslinkers (Figure S2B). Thus, crosslinks that occur within
NAC to AtxQ78 regions adjacent to the polyglutamine tract
may reflect the direct interaction between NAC and the PolyQ
region, which we observed in vitro (Figures 1C and 1D). We
incubated AtxQ78 with human NAC and used the amine-reac-
tive homobifunctional crosslinker BS3 to trap transient chap-
erone interactions. Crosslinked NAC-AtxQ78 complexes visible
on Coomassie-stained gels (Figure S2C) were excised, and
crosslinked peptides were identified by LC-MS using StavroX
(Go¨tze et al., 2012). Strikingly, 11 out of 18 identified intermo-
lecular crosslinks were to the C-terminal region of AtxQ78 close
to the expanded PolyQ stretch (Figure 2C, Table S1). These
data suggest that NAC acts by binding at, or close to, the
PolyQ tract to suppress aggregation of AtxQ78, which agrees
with the observed NAC effect on the pure PolyQ51 substrate732 Molecular Cell 74, 729–741, May 16, 2019(Figures 1C and 1D). Interestingly, NAC pre-
dominantly crosslinked to AtxQ78 via the
N-terminal regions of aNAC and bNAC (Fig-
ure 2C, Table S1), suggesting that a crucial
PolyQ binding site is located in these do-mains. However, single crosslinks were also identified to the
NAC domains, the UBA domain of aNAC, and to the C-terminal
domain of bNAC.
The Ribosome-Binding Domain of NAC Exerts
Chaperone Activity
Our data show that NAC exhibits direct chaperone activity
toward diverse PolyQ substrates. Previous crosslinking data
(Martin et al., 2018; Wiedmann et al., 1994) and our AtxQ78-
NAC crosslinking-MS analysis indicate that NAC may interact
with protein clients via both subunits. However, the specific sub-
strate-binding site(s) of NAC critical for its chaperone function
are unknown. To answer this, we took a mutational approach
based on the evolutionarily conserved regions of NAC including
the NAC dimerization domains, the C-terminal UBA domain of
aNAC, and the N-terminal ribosome-binding domain of bNAC
harboring a conserved ribosome-binding motif (RRKxxKK)
(Figure 3A). First, we asked which of these conserved domains
may be crucial for preventing PolyQ aggregation in vivo. We
generated three C. elegans strains overexpressing mutant NAC
constructs under the control of themyo-3 promoter in the back-
ground of the PolyQ35::YFP strain. These included two deletion
mutants lacking either the conserved aNAC UBA domain
(DUBA-NAC) or the N-terminal bNAC domain (DNb-NAC), as
well as a mutation in the conserved ribosome-binding motif in
the N terminus of bNAC (29RRK/AAA31-NAC) (Figure 3A), the
latter of which abolished ribosome-binding of NAC in vivo (Fig-
ure S3A). All the NACmutants expressed in C. eleganswere sta-
ble and the expression levels were comparable to that of the
overexpressed wild-type NAC complex (see FLAG immunoblot
in Figures 3D and S3B). We assessed PolyQ35::YFP aggregation
in these animals on day 3 of adulthood by fluorescence micro-
scopy as well as SDD-AGE. We observed that both the DUBA-
NAC and the RRK/AAA-NACmutants suppressed PolyQ35::YFP
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aggregation similarly to WT-NAC, indicated by the increased
diffuse PolyQ35::YFP signal in the head region of these animals
in comparison to control worms (ev) in which the majority of the
PolyQ35::YFP is aggregated in puncta (Figure 3C). This corre-
lated well with the levels of aggregated PolyQ35::YFP detected
by SDD-AGE (Figure 3D). Thus, neither the UBA domain nor ribo-
some-association of NAC is required to suppress PolyQ35::YFP
aggregation. The latter finding suggests that NAC may serve
additional chaperone functions off the ribosome in C. elegans.
These data were intriguing because analysis of NAC distribution
in yeast shows it is almost exclusively associatedwith ribosomes
(Raue et al., 2007). However, polysome profile analysis of NAC
distribution in both C. elegans and human cells showed that a
large fraction of NAC was not associated with ribosomes (Fig-
ures 3B and S3C), suggesting that NAC may also exert a post-
translational chaperone function in vivo. The finding of a large
pool of non-ribosome associated NAC under steady-state con-
ditions inC. elegans and human cells together with the observed
aggregation suppression activity of a NAC variant that does not
bind to ribosomes both support the idea of off-ribosomal chap-
erone functions for NAC in the cytosol.
Strikingly, deletion of the N-terminal domain of bNAC abro-
gated the ability of NAC to suppress PolyQ35::YFP aggregation
(Figures 3C, 3D, and S3B), indicating that this region contains an
essential interaction site for PolyQ tracts, which is consistent
with our AtxQ78-NAC crosslinking-MS data (Figure 2C). To
address this possibility directly, we tested the ability of the
different NAC mutants to suppress mHttQ51 aggregation
in vitro, using purified components. Consistent with the in vivo re-
sults, addition of purified DUBA- or RRK/AAA-NAC delayed
mHttQ51 aggregation similar to WT-NAC, whereas DNb-NAC
lost the ability to suppress aggregation (Figure 3E). In sum, the
crosslinking data combined with the in vitro and in vivo PolyQ
aggregation analyses strongly suggest that the N-terminal
domain of bNAC contains a crucial PolyQ substrate-binding
site. Importantly, our data also imply that NAC suppression of
pathogenic PolyQ aggregation via this domain can occur in a
ribosome-independent manner.
NAC Exerts Broad-Spectrum Chaperone Activity
Next, we investigated whether the identified NAC aggregation
suppression activity involving N-bNAC is PolyQ specific or re-
flects a broad-spectrum chaperone activity. As a non-PolyQ
model substrate, we used chemically denatured firefly luciferase
that is known to rely on molecular chaperones to becomeFigure 3. The Ribosome-Binding Domain of NAC Exerts Chaperone Ac
(A) Schematics showing the different heterodimeric NAC variants (a and b subu
conserved ribosome-binding motif (RRKxxKK) in the b-subunit are highlighted.
(B) Sucrose density gradient analysis in wild-type N2 worms on day 2 of adulth
Immunoblot images below show the distribution of NAC (a- and b-subunit) throu
(C) Fluorescence microscope images of PolyQ35::YFP worms overexpressingWT
3 of adulthood. Scalebar, 500 mm (upper row) and 50 mm (lower row). PolyQ35:
respectively. ev, empty vector.
(D) SDD-AGE immunoblot showing the PolyQ35::YFP aggregation in animals as in
were assessed by SDS-PAGE immunoblot analysis. Actin served as loading con
(E) In vitro filter trap aggregation assay of mutant Huntingtin (mHttQ51) incubated
was initiated by cleavage of the GST tag using the TEV protease. SDS-insoluble
See also Figure S3.
734 Molecular Cell 74, 729–741, May 16, 2019refolded and luminesce (Schro¨der et al., 1993). Indeed, we found
that luciferase activity after denaturation with guanidine-HCl
(GdmCl) was restored after addition of an ATP-driven Hsp70/
Hsp40 folding chaperone system (Figure S4A, green curve).
Interestingly, we found that purified human NAC alone had no
effect on luciferase refolding (Figure S4A, red curve) and did
not enhance luciferase refolding upon addition to the Hsp70/
Hsp40 system (Figure S4A, gray curve). However, when NAC
was added to chemically denatured luciferase first, subsequent
refolding by the Hsp70/Hsp40 system was strongly enhanced
over levels of just Hsp70/Hsp40 refolding (Figure 4A, red versus
green curve). A molar equivalent control protein of similar size,
GFP, showed no enhancing effect (Figure S4B, black curve).
Similar results were obtained with C. elegans NAC (Figure S4C,
pink curve). That NAC was only effective in the initial stages of
luciferase refolding was strikingly similar to the necessity of
NAC to be involved in the earlier stages to suppress aggregation
of mHttQ51 (Figure S1C). Thus, NAC exerts a general holdase
chaperone function and maintains unfolded luciferase or patho-
genic aggregation substrates in a soluble and refolding compe-
tent state. Importantly, we found that the activity of DNb-NAC
was significantly reduced compared to WT-NAC (Figure 4A,
yellow curve). Thus, the same domain crucial to prevent PolyQ
aggregation is also necessary to hold luciferase in a refolding
competent state. However, in contrast to the PolyQ substrates,
DNb-NAC still exerted residual chaperone activity toward dena-
tured luciferase, suggesting that NAC contains additional un-
identified chaperone domains that can bind luciferase, a protein
with higher sequence complexity than PolyQ-expanded Htt or
AtxQ78.
We further investigated NAC activity on luciferase refolding
in vivo using a C. elegans strain expressing a structurally desta-
bilized version of luciferase fused to EGFP (FlucDM-EGFP) in
muscle cells (Gupta et al., 2011). This protein is soluble at mod-
erate temperature but aggregates upon heat stress. After heat
shock (1 h, 33C) of worms, FlucDM-EGFP formed large punc-
tate aggregates that were still evident in control animals after
24 h recovery at 20C (Figure 4B, ‘‘ev’’). Overexpression of
wild-type NAC in these worms allowed FlucDM-EGFP aggrega-
tion to fully revert back to diffuse GFP signal within the 24 h
recovery phase (Figure 4B, ‘‘WT-NAC’’), showing that NAC pro-
motes in vivo refolding of luciferase, consistent with the in vitro
findings (Figure 4A). Moreover, overexpression of DNb-NAC
was inefficient to revert heat-shock-induced FlucDM-EGFP
aggregates back to the diffuse, soluble form after the 24 htivity
nit) investigated in (C)–(E). Conserved domains (NAC and UBA) as well as the
ood. Upper image shows polysome gradient profile (absorbance at 254 nm).
ghout the gradient. uL16 served as a ribosomal marker.
-NAC or different mutant NAC versions shown in (A). Images were taken at day
:YFP aggregates and cell nuclei are indicated by white and blue arrowheads,
(C). Total levels of SDS-soluble PolyQ35::YFP and FLAG-tagged NAC variants
trol.
with 53molar excess of indicated NAC variants. Aggregation of GST-mHttQ51
aggregates were detected with an S-tag antibody.
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Figure 4. NAC Exerts Broad-Spectrum Chaperone Activity
(A) In vitro chaperone refolding assays using guanidine-HCl (GdmCl)-denatured luciferase as substrate. Luciferase (0.02 mM) was preincubated with indicated
NAC variants in a 1:1 molar ratio for 15 min at room temperature, and refolding was initiated by adding an Hsp70/Hsp40 chaperone system (3.2 mM/0.8 mM).
Luciferase reactivation was analyzed by luminescence recording over 2 h at RT using luciferin as a substrate. Statistical significance was calculated by one-way
ANOVA and Tukey post hoc test. a.u., arbitrary units. *p < 0.05 (n = 3).
(B) Fluorescencemicroscope images ofC. elegansworms expressing a destabilized variant of firefly luciferase fused to EGFP (FlucDM-EGFP) and indicated NAC
variants (FLAG-tagged a and bNAC) in muscle cells. Images were taken before heat shock (HS, 1 h at 33C), directly after HS, and after 24 h recovery at 20C.
Scale bar, 20 mm. ev, empty vector.
(C) Kinetic aggregation assays of Ab40 (32 mM, blue) incubated with an equimolar concentration of WT-NAC (red) or DNab-NAC (yellow) measured using
ThioflavinT fluorescence. a.u., arbitrary units.
(D) Negative stain transmission electron micrographs of the reaction endpoint (at 20 h) for each sample shown in (C). Scale bar, 5 mm.
See also Figure S4 and Table S2.recovery period (Figure 4B, ‘‘DNb-NAC,’’ and Figure S4D). Thus,
efficient luciferase refolding depends on N-bNAC, in vitro and
in vivo. Overall, these data corroborate that the N terminus of
bNAC represents a central chaperone domain of NAC for lucif-
erase as well as for PolyQ substrates.
Next, we investigated whether NAC suppresses aggregation of
the Alzheimer’s disease-related Ab40 peptide which, in contrast
to PolyQ, has a more complex sequence, including regions
more hydrophobic in character. Ab40 aggregation was recorded
over time in vitro using Thioflavin T (ThT) fluorescence as a
readout for amyloid fibril formation. In the absence of NAC, we
observed a rapid increase of ThT fluorescence, indicating Ab40
aggregation (Figure 4C, ‘‘Buffer’’), and electron microscopeanalysis confirmed formation of aggregates with fibrillar structure
(Figure 4D). Remarkably, equimolar addition of purified human
NAC completely suppressed Ab40 aggregation and fibril forma-
tion (Figures 4C and 4D). In addition, DUBA- and RRK/AAA-NAC
mutants also fully suppressed Ab40 aggregation (Figure S4E).
However, in contrast to the PolyQ substrates and luciferase,
the N-terminal bNAC domain was dispensable for preventing ag-
gregation of the highly hydrophobic Ab40 substrate. Though
crosslinking-MS analyses indicated an interaction of Ab40 with
the N-terminal domains of NAC similar to AtxQ78 (Figures S4F
and S4G), NAC mutants lacking the bNAC N terminus
(DNb-NAC)or theN termini ofbothsubunits (DNab-NAC)were fully
active in suppressing Ab40 aggregation comparably to WT-NACMolecular Cell 74, 729–741, May 16, 2019 735
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Figure 5. Functional Characterization of the
N-Terminal bNAC Chaperone Domain
(A) (i) Peptide sequences of N-termini of bNAC
from C. elegans and humans. Positively charged
residues are highlighted in red. Both peptides
exhibit a considerably high isoelectric point (pI).
(ii) N-terminal peptide sequence of human aNAC
exhibiting in contrast to bNAC peptides a low pI.
Negatively charged residues are highlighted
in blue.
(B) In vitro filter trap aggregation assay of mutant
Huntingtin (mHttQ51) incubated with 53 or 103
molar excess of bNAC peptides shown in (A) or
full-length NAC protein.
(C) (i) Chemical reaction scheme showing acyla-
tion of primary amines by Sulfo-NHS-acetate used
to neutralize the positive charge in lysine residues
of bNAC peptides shown in (A). (ii) In vitro filter trap
aggregation assay of mutant Huntingtin (mHttQ51)
incubated with 53 molar excess of peptides
shown in (A) with and without Sulfo-NHS-acetate
labeling.
(D) In vitro filter trap aggregation assay of mutant
Huntingtin (mHttQ51) incubated with 53 molar
excess of full-length NAC protein (NAC),
full N-terminal bNAC peptide (Full N-term), or the
N- and C-half of the peptide as indicated in the
schematic below (N- and C-half highlighted in blue
and red, respectively).
(E) In vitro filter trap aggregation assay of mutant
Huntingtin (mHttQ51) incubated with 53 or 103
molar excess of human a- or bNAC peptides
shown in (A).
See also Figure S5.(Figures 4C, 4D, and S4E). Thus, NAC likely contains other impor-
tant substrate interaction sites that may specifically bind hydro-
phobic segments in substrates such as Ab40 and luciferase.
In sum, these data show that NAC is able to chaperone diverse
substrates with different structural and physicochemical proper-
ties, corroborating a broad-spectrum chaperone function of
NAC. Moreover, our data reveal that the N-terminal bNAC
domain confers substrate-specific chaperone function.
Functional Characterization of the N-Terminal bNAC
Chaperone Domain
Our data show that the N-terminal domain of bNAC not only
confers ribosome-binding but also has chaperone activity, pre-
venting the aggregation of PolyQ proteins and promoting
refolding of firefly luciferase. This small domain (40 aa) is
characterized by a high positive net charge, in particular at its
C-terminal half, which is predicted to be unstructured (Fig-
ure 5A). To gain more insight into the chaperone activity of
this domain, we utilized synthetic peptides corresponding to
the N-terminal region of bNAC from human and C. elegans in
in vitro aggregation assays. We observed that these N-bNAC
peptides alone were sufficient to suppress aggregation of
mHttQ51 (Figure 5B). Similar aggregation suppression results
were obtained when using the pure PolyQ51 substrate (Fig-736 Molecular Cell 74, 729–741, May 16, 2019ure S5A), indicating a direct interaction of the N-bNAC peptides
with the polyglutamine stretch.
Themost obvious characteristic of the N-bNAC peptides is the
high positive net charge (Figure 5A). In addition to hydrophobic
contacts, electrostatic interactions mediated via highly charged
regions in chaperones are emerging to play an important role in
client binding (He et al., 2016; Horowitz et al., 2016; Joachimiak
et al., 2014). Thus, we asked whether the positively charged res-
idues contribute to the ability of these peptides to suppress
PolyQ aggregation. To address this, we acylated primary amines
in lysine residues of the peptides using Sulfo-NHS-acetate in
order to neutralize the positive charge (Figures 5Ci and S5B).
Interestingly, we observed that upon labeling the lysine residues,
the peptides significantly lost their ability to suppress mHttQ51
aggregation (Figure 5Cii). Thus, the positively charged residues
in N-bNAC are critical for its chaperone activity. To investigate
this in more detail, we split the human peptide into two halves,
resulting in an N-terminal peptide containing a predicted
conserved helical element with several hydrophobic residues
and a C-terminal peptide encompassing most of the conserved
positively charged residues (Figure 5D). Remarkably, the C-ter-
minal half of N-bNAC was alone able to suppress mHttQ51
aggregation, whereas the N-terminal half showed no effect (Fig-
ure 5D). This finding corroborates that the primary PolyQ binding
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Figure 6. NAC Suppresses Toxicity of PolyQ Proteins
(A) Viability of mouse striatal neurons either homozygous for wild-type Huntingtin (Q7/7) or heterozygous for mutant Huntingtin (Q7/111). Metabolically active cells
were quantified by measuring ATP levels using the Cell Titer Glo assay after 3-day treatment with siRNAs targeting both NAC subunits. Scrambled (Scrm) siRNA
sequences were used as control. Data are represented asmean ± SEM. Statistical significance was determined by two-way ANOVA. Data are representative of at
least 5 independent biological replicates. a.u., arbitrary units.
(B) Quantification of a/bNAC knockdown by qPCR in the mouse striatal cell lines Q7/7 and Q7/111. Actin was used as a housekeeping gene control. Knockdown
of a/bNAC was compared to the scrambled control condition.
(C) (i) Homozygous wild-type (Q7/7) and heterozygous mutant (Q7/111) Huntingtin cells were treated with NAC siRNA or a scrambled control (Scrm) for 3 days.
Fluorescence microscope images show cells stained with Proteostat fluorescent dye to assess protein aggregation. Cells treated with the proteasome inhibitor
MG132 (5 mM, 6 h) were used as positive aggregation control. Scale bar, 15 mm.Hoechst was used to label nuclei of cells. (ii) Diagram shows the ratio of Proteostat
fluorescence to Hoechst fluorescence in cells shown as in (i). Data are represented as mean ± SEM (n = 3).
(legend continued on next page)
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site is located in the positively charged stretch of the peptide.
Although very potent, the C-terminal peptide was not as
completely effective as the full-length peptide or the full-length
NAC chaperone in suppressing mHttQ51 aggregation (Fig-
ure 5D). This suggests that additional regions in the N-bNAC
peptide contribute to the chaperone activity. Of note, mixing
the N-half peptide and the C-half peptides did not increase the
aggregation suppression ability over the C-half peptide alone
(Figure 5D). Thus, full function is only obtained by a cooperative
activity that relies on the entire N-bNAC.
We also investigated the activity of the N terminus of the aNAC
subunit, which is also highly charged, albeit with a net negative
charge (Figure 5A). This domain is thought to be flexible, similar
to the bNAC N-terminal region, and our AtxQ78-NAC crosslink-
ing data indicated an interaction with the mutant PolyQ domain
(Figure 2C). However, we found that N-aNAC peptides either
added alone or in combination with the N-bNAC peptides had
no effect on mHttQ51 aggregation (Figures 5E and S5C), even
at 103molar excess over the mHttQ51 substrate, underscoring
the specificity of the aggregation suppression effect by the posi-
tively charged bNAC N-terminal domain.
NAC Suppresses Toxicity of PolyQ Proteins in Neuronal
Cell Lines and Animals
Next, we investigated the relevance of NAC to mutant Huntingtin
toxicity in neuronal cells. Here, we used a knockin mouse striatal
cell line heterozygous for a 111-glutamine residue repeat muta-
tion in the full-length Huntingtin protein (HttQ7/111), which is a
well-established cell line to model Huntington’s disease
pathology (Trettel et al., 2000). We compared the phenotype of
this mutant Huntingtin cell line with that of a striatal mouse cell
line homozygous for the wild-type Huntingtin allele (HttQ7/7).
First, we assessed how knockdown of NAC would affect viability
of mHtt-expressing cells. We depleted both NAC subunits by
siRNA, and after 72 h determined the number of metabolically
active cells by measuring ATP levels using the Cell Titer Glo
assay. While knockdown of NAC decreased health of both cell
lines, the mHtt-expressing HttQ7/111 cells were significantly
more sensitive toward NAC depletion (Figure 6A). Knockdown
efficiency of aNAC and bNAC was comparable in two Htt cell
lines (Figures 6B and S6). Thus, while NAC generally promotes
striatal neuron health, NAC is especially critical tomaintainmeta-
bolic health of neurons expressing mutant, aggregation-prone
Huntingtin. To address whether ribosome-binding of NAC was
necessary for this protective function, we tried to overexpress
different NAC variants in striatal cells. However, this was not
possible, so it remains unclear whether suppression of Htt
toxicity in neurons by NAC results from its co- and/or post-trans-
lational function.
To understand the specific need for NAC in maintaining meta-
bolic function of mHtt-expressing striatal neurons, we asked
whether NAC was especially crucial for neuronal protein homeo-
stasis in the presence of mutant Huntingtin. Therefore, we(D) Diagram shows the percentage of non-paralyzed PolyQ35::YFP C. elegan
deficient NAC (RRK/AAA), or NAC lacking the N-terminal region of bNAC (DNb-NA
(n = 3). Statistical significance was calculated by Student’s t test. **/***p < 0.01/0
See also Figure S6.
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(HttQ7/7) and mutant Htt-expressing cells (HttQ7/111) upon
silencing of NAC. Protein aggregation was assessed using the
Proteostat dye, which recognizes aggregates from a broad
range of protein substrates (Shen et al., 2011). We observed
that in wild-type cells, knockdown of NAC had a negligible effect
on protein aggregation, whereas protein aggregates strongly
accumulated in the mHtt-expressing cells (Figure 6C). Thus,
NAC is essential to counteract the increased burden on the pro-
tein homeostasis machinery provoked by mHtt expression,
demonstrating the essential, physiologically protective role
NAC plays in maintaining protein homeostasis.
Finally, because protein aggregation has been tightly linked to
age-associated organismal degeneration (Sala et al., 2017), we
asked whether NAC is also essential for organismal fitness and
healthy aging. We overexpressed wild-type NAC and mutant
DNb-NAC in C. elegans expressing the aggregation-prone
PolyQ35::YFP and measured age-associated paralysis (Cohen
et al., 2006; Morley et al., 2002). We found that overexpressing
wild-type NAC significantly improves motility of PolyQ35::YFP-
expressing worms during aging (Figure 6D), suggesting that
overexpression of NAC alone can improve protein homeostasis
and organismal health. In addition, we found that this improve-
ment in motility strictly depends on the presence of the N
terminus of bNAC (Figure 6D), highlighting the importance of
this domain in maintaining protein homeostasis in aging. Impor-
tantly, the protective activity of N-bNAC is mostly independent
from its ribosome-binding role as overexpression of the ribo-
some-binding deficient RRK/AAA-NAC variant still improved
motility during aging, albeit less effective than WT-NAC (Fig-
ure 6D). Thus, ribosome-binding of NAC contributes but is not
essential under these conditions per se for improving protein
homeostasis and organismal health in aging. Overall, these
data show the tight linkage between cellular and organismal pro-
teostatic health and the chaperone role of NAC as mediated by
the N terminus of the bNAC subunit.
DISCUSSION
Our data show that the same domain of NAC critical for ribo-
some-binding also exerts chaperone activity. Thus, N-bNAC
has a dual role and may serve chaperone functions on and off
the ribosome. NAC may contact nascent substrates via
N-bNAC to promote co-translational folding, and, likewise, this
domain binds misfolded cytosolic proteins post-translationally
to prevent aggregation. Indeed, NAC exists in an equilibrium be-
tween a ribosome-bound and unbound state under steady-state
conditions with a large non-ribosomal population. Our data also
clearly show that the chaperone function of NAC is not restricted
to co-translational de novo protein synthesis as revealed by the
ribosome-independent aggregation suppression effect of NAC
on PolyQ proteins in vivo and in vitro. We suggest a model in
which the canonical activity of NAC in co-translational proteins worms overexpressing either wild-type NAC (WT-NAC), ribosome-binding
C) between days 6 and 10 of adulthood. Data are represented as mean ± SEM
.001 versus WT-NAC. EV, empty vector.
transport and folding (del Alamo et al., 2011; Gamerdinger et al.,
2015) is complemented by its off-ribosomal chaperone activity to
prevent aggregation of misfolded cytosolic protein species.
Whether ribosome-associated NAC also actively dissociates
from the ribosome during protein stress to chaperone aggrega-
tion-prone substrates is an attractive hypothesis and remains to
be further explored. Previous data suggested an elegant mech-
anism for how NAC binding to misfolded protein species might
be coupled to ribosome detachment under high proteotoxic
stress (Kirstein-Miles et al., 2013). This stress-induced ribosome
dissociation of NAC could be mediated by other chaperone co-
factors activated by the presence of protein aggregation or by
bulk association upon accumulation of protein aggregates.
NAC has broad chaperone activity toward distinct types of
substrates, including PolyQ, Ab40, and luciferase. The type of
misfolded or unfolded domain that NAC recognizes remains un-
clear. We find that NAC is most effective in the early stages of
misfolding of aggregation-prone pathogenic proteins (Fig-
ure S1D). This suggests that NAC may act as a holdase chap-
erone that recognizes a misfolded intermediate appearing early
in the aggregation reaction. NAC may then prepare these
early-aggregation species substrates for further manipulation
by other chaperones as demonstrated for luciferase in this study
(Figure 4A) or sequester aggregation-prone domains critical in
the early stages of oligomerization. It is tempting to envision a
similar activity for NAC when acting on nascent polypeptides.
The affinity of NAC for different misfolded protein domains re-
mains to be determined, and affinity may well depend both on
the sequence and conformational properties of the client, as is
observed for other ATP-independent chaperones (Saio et al.,
2014; Stull et al., 2016). Our in vitro experiments demonstrate a
concentration dependence of NAC suppression of PolyQ aggre-
gation (Figure S1B), with higher molar excess of NAC over the
client resulting in greater aggregation suppression. Such an
observation is consistent with findings on other ATP-indepen-
dent chaperones that bind their substrates weakly, such that
an excess of chaperone is required to enable chaperone binding
to compete effectively with aggregation. Importantly, NAC is an
abundant protein in vivo and is at least stoichiometric with the
ribosome (Raue et al., 2007), which would enable effective
chaperoning even for weakly binding clients that are highly
aggregation-prone. Thus, even if only a small percentage of
NAC associates with misfolded Htt substrates at any given
time, rapid binding and release, combined with potential remod-
eling of the protein client in the bound state, could also enhance
folding and decrease the probability of aggregation. This would
enable these proteins to remain soluble so that they can fold
spontaneously or be bound by other chaperones that complete
folding or target misfolded proteins to degradation pathways
(Balchin et al., 2016; Saibil, 2013).
The discovery that just the positively charged N terminus of
bNAC is sufficient to potently suppress mutant PolyQ aggrega-
tion in vitro, as well as necessary to delay age-associated paral-
ysis in C. elegans, has important implications for a general
binding mechanism of chaperones to mutant PolyQ substrates.
While the PolyQ itself is uncharged, its polarity can still take
part in weak electrostatic interactions with a charged surface
like the bNAC N terminus. Indeed, hydrophilic regions havebeen associated with chaperone-substrate recognition patterns
in addition to the more canonical hydrophobic regions. For
example, the TRiC chaperonin, a potent suppressor of mHtt
aggregation and toxicity, contains bipartite hydrophilic and
hydrophobic substrate recognition sites (Joachimiak et al.,
2014). It has been proposed that both of these domains may
recognize either hydrophobic or hydrophilic regions of mHtt to
mediate suppression of aggregation (Joachimiak et al., 2014;
Tam et al., 2006, 2009). DNAJB6 suppresses aggregation of
expanded PolyQ tracts through a serine/threonine-rich domain,
which disrupts formation of stabilizing hydrogen bonding among
the PolyQ residues (Kakkar et al., 2016). It is intriguing that there
seems to be specificity with respect to charge: while the N-termi-
nal region of the aNAC subunit is also highly charged, it is net
negatively charged and has little to no effect on Htt aggregation
(Figure 5E). Thus, it seems that an overall net positive charge is
specific for suppression of PolyQ aggregation, but reasons
why are still unclear.
Finally, the ability of the bNAC N-terminal peptide to suppress
aggregation makes this an important sequence for possible ther-
apeutic development. How NAC is able to recognize different
misfolded substrates is an intriguing question for further explora-
tion. A strong overexpression of full-length NAC is poorly
tolerated on the organismal level (Gamerdinger et al., 2015),
potentially due to its binding mode at the ribosomal exit site
that is competitive with other essential protein biogenesis fac-
tors. This restricts a potential therapeutic intervention strategy
that aims to increase NAC expression levels to combat PolyQ
diseases. However, delivery or overexpression of just the
N-terminal peptide, which is sufficient to suppress PolyQ aggre-
gation, may be much better tolerated in an organism and thus an
effective an anti-aggregation therapeutic strategy. In sum, this
study provides a detailed understanding of a chaperone activity
of NAC off the ribosome and highlights a substrate recognition
mechanism that is based on positive charges which provides a
possible avenue for a peptide-based therapeutics approach in
Huntington’s disease and related PolyQ disorders.STAR+METHODS
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GFP Covance RRID:AB_10063778
FLAG Sigma-Aldrich RRID:AB_262044
Actin Santa Cruz RRID:AB_2714189
Beta-NAC (BTF3) Abcam RRID:AB_1141066
HRP-anti-mouse IgG Jackson RRID:AB_2340771
HRP-anti-rabbit IgG Jackson RRID:AB_ 2340585
Alpha-NAC/Beta-NAC (C. elegans) Kirstein-Miles et al., 2013 N/A
uL24 (C. elegans) Deuerling lab N/A
uL16 (RPL10L) Abgent Cat#AP17603a
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Anti-6x HIS tag Abcam RRID:AB_2732046
RPLP0 Immunovision Cat#HPO-0100
Tubulin Gift from Thomas Mayer,
University of Konstanz
N/A
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OP50 CGC Strain OP50
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Human betaNAC N-term peptide Genscript Custom order, C-terminal amidation
Human betaNAC N-term peptide (N-half) Genscript Custom order, C-terminal amidation
Human betaNAC N-term peptide (C-half) Genscript Custom order, C-terminal amidation
Human alphaNAC N-term peptide Genscript Custom order, C-terminal amidation
Sulfo-NHS Acetate Thermo-Fisher Cat#26777
GST-mHttQ51 recombinant protein This paper N/A
GST-Q51 recombinant protein This paper N/A
Ataxin-3 recombinant protein This paper N/A
NAC recombinant variants (C. elegans + human) This paper N/A
Ovalbumin Sigma-Aldrich Cat#A5503
acTEV protease Thermo-Fisher Cat#12575015
TNBS G Biosciences Cat#BC86
Glutathione Sepharose 4B GE Healthcare Cat#17-0756-05
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Cellulose acetate membrane OE66 GE Healthcare Cat#10404180
7K MWCO Zeba Spin desalting columns Thermo Fisher Cat#89882
Strataclear Resin Agilent Cat#400714
BS3-d0/BS3-d4 (used for Ataxin-3-NAC xlinking) Thermo-Fisher Cat#10066323
Q Sepharose Fast Flow GE Healthcare Cat#17051001
GeneRuler 1 kb Thermo-Fisher Cat#SM0312
BS3-H12/BS3-d12 (used for Abeta40-NAC xlinking) Creative Molecules Cat#001SS
Ulp-1 Deuerling lab N/A
Hsp-1 (Hsp-70) This paper N/A
Dnj-13 (Hsp40) This paper N/A
Firefly Luciferase This paper N/A
Protein G Agarose Thermo-Fisher Cat#20398
Critical Commercial Assays
Proteostat Aggresome Detection Kit Enzo Life Sciences Cat#ENZ-51035-K100
CellTiter-Glo Luminescent Cell Viability Assay Promega Cat#G7572
Experimental Models: Cell Lines
ST HDH Q7/7 Coriell Cell Repositories Cat#CH00096
ST HDH Q7/111 Coriell Cell Repositories Cat#CH00097
HEK293T ATCC Cat# CRL-3216
Experimental Models: Organisms/Strains
N2 CGC WormBase ID: N2
AM140 rmIs132 [unc-54p::Q35::YFP] CGC AM140
FlucDM-EGFP marIs135 [unc-54p::FlucDM::EGFP] Ulrich Hartl, Gupta et al., 2011 N/A
Oligonucleotides
alphaNAC siRNA Dharmacon Cat#L-041821-01-0005
betaNAC siRNA Dharmacon Cat#L-052370-01-0005
Scrambled siRNA Dharmacon Cat#D-001206-14-05
Recombinant DNA
pET11a-ataxin3-78Q Generated in Radford lab. Orginal
construct from Sandra Macedo-
Ribeiro (Instituto de Biologia Molecular
e Celular and Instituto de Investigac¸a˜o
e Inovac¸a˜o em Sau´de, University of Porto)
N/A
pETSac-mAb40 Provided by Dr. Sara Linse (Lund University,
Sweden) and Prof. Dominic Walsh (Harvard
Institute of Medicine, USA).
N/A
pCFJ90 (myo-2p::mCherry) Addgene, Frøkjaer-Jensen et al., 2008 RRID:Addgene_19327
pPD61_125 Addgene, gift from Andrew Fire RRID:Addgene_1508
pPD61_125_myo-3p::3xFLAG-alphaNAC::
unc-53-30utr
This paper N/A
pPD61_125_myo-3p::3xFLAG-betaNAC::
unc-53-30utr
This paper N/A
pPD61_125_myo-3p::3xFLAG-deltaUBA-
alphaNAC::unc-53-30utr
This paper N/A
pPD61_125_myo-3p::3xFLAG-RRK/AAA-
betaNAC::unc-53-30utr
This paper N/A
pPD61_125_myo-3p::3xFLAG-deltaN-
betaNAC::unc-53-30utr
This paper N/A
p6xHis-SUMO-Hsp-1 (Hsp70 expression vector) This paper N/A
p6xHis-SUMO-Dnj-13 (Hsp40 expression vector) This paper N/A
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pDS56-6xHis-Luciferase This paper N/A
p6xHis-SUMO-alphaNAC/betaNAC (C. elegans) Kirstein-Miles et al., 2013 N/A
p6xHis-SUMO-alphaNAC/betaNAC (human) This paper N/A
p6xHis-SUMO-alphaNAC/RRK/AAA-betaNAC
(C. elegans)
This paper N/A
p6xHis-SUMO-alphaNAC/deltaN-betaNAC
(C. elegans)
This paper N/A
p6xHis-SUMO-deltaUBA-alphaNAC/betaNAC
(C. elegans)
This paper N/A
p6xHis-SUMO-deltaN-alphaNAC/deltaN-
betaNAC (human)
This paper N/A
Software and Algorithms
Fiji Image software Schindelin et al., 2012 https://fiji.sc/
Prism 7 Graphpad https://www.graphpad.com/
scientific-software/prism/
MassLynx 4.1 Waters http://www.waters.com/waters/
en_US/MassLynx-MS-Software
Peaks 7/8 Bioinformatics Solutions http://www.bioinfor.com/peaks-
studio/
StavroX Go¨tze et al., 2012 https://www.stavrox.com
Image Studio Lite Li-Cor https://www.licor.com/
ImageJ NIH https://imagej.nih.gov/ij/
WinDaq DataQ Instruments https://www.dataq.comCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to Lead Contact Elke Deuerling (elke.deuerling@uni-konstanz.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Cell lines (ST HDH Q7/7 and ST HDH Q7/111) were purchased from the Coriell Cell Repository and not authenticated for this study.
Cells were cultured in DMEM under 5% CO2.
C. elegans strains
C. elegans strain AM140 (rmIs132 [unc-54p::Q35::YFP]) was obtained from Caenorhabditis Genetics Center (CGC). Strain FlucDM-
EGFP (marIs135 [unc-54p::FlucDM::EGFP] (Gupta et al., 2011) was obtained fromUlrich Hartl, Max-Planck-Institute of Biochemistry,
Martinried, Germany. Worms were cultured according to standard techniques with E. coli OP50 as food source (Brenner, 1974).
METHOD DETAILS
Protein purification
PolyQ51 and mHttQ51 (Exon 1 of HTT with 51 glutamine repeat) plasmids were constructed as previously described (Tam et al.,
2006). Proteins were expressed in Rosetta 2(DE3) pLysS competent cells (Agilent Technologies) in LBmedia supplemented with car-
benicilin and chloramphenicol. Cultures were induced with 1 mM IPTG for 2.5h at 16C. For purification, pellets were resuspended in
50 mM sodium phosphate, pH 8.0; 150 mM NaCl; 1 mM EDTA and lysed using an Emulsiflex (Avestin). Lysate was incubated with
GSH-Sepharose resin (GE Healthcare) and washed with 0.1% (v/v) Triton, 500 mM NaCl, and 5 mM Mg-ATP before eluting protein
with 15 mM glutathione. Protein was concentrated and buffer exchanged with 50 mM Tris-HCl, pH 8.0; 100 mM NaCl; 5% (v/v)
glycerol. Concentrated protein was 0.2 mm filtered before storage at 80C.
Wild-type NAC and NAC mutants from both human (aNAC = NACA; bNAC = BTF3) and C. elegans (aNAC = icd-2; bNAC = icd-1)
were recombinantly expressed in Rosetta (DE3) cells as His-SUMO fusion constructs. Cultures were induced with 0.5 mM IPTG over
night at 20C. Cell pellets were resuspended in lysis buffer (20 mM sodium phosphate pH 7.5, 300 mM NaCl, 6 mM MgCl2, 2 mMe3 Molecular Cell 74, 729–741.e1–e7, May 16, 2019
b-mercaptoethanol, 2 mM PMSF, 10 mg/mL DNase I, 10% (v/v) glycerol) and lysed by French Press. Proteins were captured using
Ni-IDA matrix (Protino; Macherey-Nagel) and eluted with lysis buffer containing 250 mM imidazole. Elution fractions were dialyzed
overnight in the presence of 8 mg Ulp-1 per mg protein for proteolytic cleavage of the His-SUMO tag. Ion exchange chromatography
using Resource Q column (GEHealthcare) was used for further purification. Elution fractions containing aNAC and bNAC in a 1:1 ratio
were pooled, frozen in liquid nitrogen and stored at 80C.
His-tagged AtxQ78 (ATXN3) was purified as described in Scarff et al. (Scarff et al., 2015) using nickel affinity chromatography and
size-exclusion chromatography.
Ab40 peptide was expressed and purified as described previously (Stewart et al., 2017; Walsh et al., 2009). In short, BL21 (DE3)
cells were transformed with pETSac-mAb40. Expression of Ab40 was induced by the addition of IPTG to a final concentration of
1 mM. The cells were allowed to grow for an additional three hours before collection. Inclusion bodies were extracted from the cells
by means of sonication followed by centrifugation. Ab40 was purified from the inclusion body lysate by Q-Sepharose purification
followed by two rounds of SEC. The purified peptides were lyophilized and stored at20C. The purity of the peptides was confirmed
by SDS-PAGE and LC-MS.
In vitro aggregation assays
Mutant Huntingtin and PolyQ51 aggregation reactions were performed at concentration 3 mMof mHttQ51, 0.044 Units/ml acTEV pro-
tease (Invitrogen, Carlsbad, CA, USA), and respective concentrations of Ovalbumin (Sigma) or purified NAC chaperone variants.
Aggregation was conducted in TEV reaction buffer (Invitrogen) and incubated at 30C. AtxQ78 was buffer exchanged into TEV reac-
tion buffer using 7KMWCOZeba Spin Desalting Columns (Thermo Fisher) to initiate aggregation. AtxQ78 aggregation reactions were
performed at 30 mM of Ataxin-3 in reaction buffer (20 mM sodium phosphate pH 7.5, 25 mM NaCl, 6 mMMgCl2, 2 mM DTT, 5% (v/v)
glycerol) and incubated at 37C. Samples at varied time-points were then taken and combined in a 1:1 ratio with a 4% (w/v) SDS,
100 mMDTT solution, boiled for 5 min at 95C, and stored at20C. Samples were then filtered through a 0.22 mm cellulose acetate
membrane (Whatman) and washed with 0.1% (w/v) SDS. Membrane was probed using an S-tag antibody (Abcam) for mHttQ51 and
PolyQ51, and with a His-tag antibody (Abcam) for AtxQ78.
Thioflavin T fluorescence assay
Lyophilized Ab40 was resuspended at 320 mM in 20 mM sodium phosphate pH 7.4, 0.2 mM EDTA, 0.01% (w/v) sodium azide and
stored on ice. The NAC proteins were diluted to 100 mM in storage buffer (20 mM sodium phosphate pH 7.5, 25 mM NaCl,
6 mM MgCl2, 2 mM b-mercaptoethanol, 5% (v/v) glycerol) and buffer exchanged into 20 mM sodium phosphate pH 7.4, 0.2 mM
EDTA, 0.01% (w/v) sodium azide, 1x completeTM mini protease inhibitor, EDTA free (Roche) by means of ZebaSpin 7 kDa MWCO
spin columns (Thermo Scientific). Samples were prepared that contained equimolar concentrations of Ab40 and NAC variants. Thi-
oflavin T was added to a final concentration of 10 mM. The samples were transferred to a 96 well half-area clear bottom microplate
(Corning GmbH, Wiesbaden, Germany), with 95 mL of sample in each well. The fluorescence (excitation: 440 nm, emission: 480 nm)
was measured using a BMG Omega plate reader (BMG Labtech) incubating samples at 37C, quiescently.
Transmission electron microscopy
After 20 h, samples were taken from the Thioflavin T plate and fixed on carbon coated copper grids, made in house. The samples
were negative stained with 2% (w/v) uranyl acetate. The samples were imaged on a JEOL 1400 TEM at the Astbury structural biology
laboratory, University of Leeds.
Cell viability assays and real-time PCR
siRNA knockdown was completed using the DharmaFECT reverse transfection protocol. Striatal knock-in cell lines (homozygous
wild-type HttQ7/7 and heterozygous mutant HttQ7/111) were plated in 96-well plates (1.25 3 10^4 cells/well) in complete medium
(DMEMwith high glucose, 10%FBS) at 32C. Experiments were plated to have four technical replicates per siRNA treatment for each
experiment, with each independent experiment repeated at least three times. 72 hours post transfection, cells were incubated with
Cell Titer Glo reagent (Promega) for at least 10 min before recording luminescence signal. For real-time PCR (RT-PCR), RNA was
harvested from cells using the Zymo Quick-RNA kit, cDNA was synthesized using the iScript kit. RT-PCR was completed using
the SYBR Green Master Mix from Biorad and fold-knockdown was calculated using the 2–DDCt method.
Fluorescence microscopy of cells
Cells were imaged on a Zeiss LSM 700 confocal microscope (Carl Zeiss). Cells were prepared similarly as above but plated on a poly-
lysine coated coverslip in 24-well plate. Post transfection, the cells were stained with a 1:2000 Proteostat solution (Enzo Life
Sciences, Farmingdale, NY, USA) for 1 hour, followed by a 0.67 mg/mL Hoechst stain for 5 min, prior to imaging. For proteasome
inhibition, cells were treated with 5 mM MG132 for 6 hours prior to imaging.
Polysome analysis in human cells
Prior to harvesting, HEK293T cells were treated with 100 mg/mL cycloheximide (CHX) for 5 min at 37C. Cells were then washed twice
in 100 mg/mL CHX in PBS and harvested in the same buffer on ice. Pelleted cells were then resuspended in lysis buffer (10 mMMolecular Cell 74, 729–741.e1–e7, May 16, 2019 e4
HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 1% Triton X-100, 100 mg/mL CHX) and lysed by trituration through a 26G
needle for 10 passes. The sample was centrifuged at 1500 x g for 5 min at 4C. RNA concentration of the supernatant was then
measured by Nanodrop. 200 mg (in RNA) of lysate was loaded onto a 12 mL 10%–50% (w/v) linear sucrose gradient (Gradient
Mate, Biocomp Instruments) prepared in gradient buffer (100 mM KCl, 20 mM HEPES pH 7.6, 5 mM MgCl2, 100 mg/mL CHX,
1U/ml RNase inhibitor) and centrifuged for 2 h at 36000 rpm in a swinging bucket rotor (SW-41, Beckmann). Gradients were then frac-
tionated from top to bottom with a density gradient fractionator (Brandel), and A260 was monitored to detect cytosolic fractions, ri-
bosomal subunits, monosomes, and polysomes. Data were recorded and processed with WinDaq (Dataq Instruments). For one
gradient, 15 fractions with 1 mL each were collected. For subsequent western analysis, 500 ml of gradient buffer and 10 ml of Stra-
taclear resin slurry (Agilent Technologies) was added to each fraction and incubated on rotation at 4C. Fractions were centrifuged
twice at 3000 x g at 4C for 5 min to remove supernatant. The remaining resin was then resuspended in 20 ml 2X Laemmli Buffer,
centrifuged at 3000 x g for 5 min, and the residual supernatant was loaded into an SDS-PAGE gel and then transferred onto a nitro-
cellulose membrane. Different dilutions of primary antibodies were applied (1:400 anti-bNAC, 1:3000 anti-RPLP0).
Sulfo-NHS peptide labeling
NAC N-terminal peptides were ordered from Genscript. Peptides were dissolved to 1 mM in 0.1 M sodium carbonate buffer, pH 8.5.
Peptide solutions were added to a 25-fold molar excess of Sulfo-NHS Acetate (Thermo Scientific, Waltham, MA, USA) to amine
groups in the sample and incubated for 1 hour at room temperature. Reaction was quenched using a 1 M Tris-HCl, pH 7.5 solution.
To quantify the efficiency of this labeling, a lysine standard curve was established; samples were assayed for free primary amines by
adding 0.01% (w/v) TNBS in 0.1M sodium bicarbonate, pH 8.5 solution (G Biosciences) to each sample and standard, and incubated
at 37C for 2 hours. 10% SDS and 1N HCl was then added to stop the reaction. Absorbance was measured at 335 nm.
Chemical crosslinking and mass spectrometry
For crosslinking AtxQ78 was buffer exchanged into 10mM sodium phosphate (pH 7.2) and added to NAC at a 1:1 ratio (20 mMNAC +
20 mMAtxQ78). A 1:1 mixture of BS3-d0 and BS3-d4 was added to the proteins at 20x and 50x molar excess and the reaction allowed
to proceed at room temperature for 1 hour before quenching with the addition of 50 mM Tris-Cl (pH 7.5). Samples were diluted with
2x loading buffer and separated on Tris-tricine gels followed by staining with InstantBlue (Expedeon).
Ab40 (18 mM) was incubated with purified NAC in a 1:1 molar ratio in Ab aggregation buffer (20 mM sodium phosphate pH 7.5,
0.2 mM EDTA, 0.01% (w/v) NaN3) at 37
C for 2 h. BS3-h12d12 was added to the proteins at 20x molar excess and incubated for
30 min at 37C before quenching with 50 mM NH4HCO3. Crosslinked samples were gel-filtrated using a Superdex 75 column
(GE Healthcare) and fractions containing crosslinked Ab40-NAC complexes subjected to co-immunoprecipitation using Ab antibody
6E10 (Biozol). Captured proteins were denatured with 1x SDS sample buffer under non-reducing conditions to avoid splitting of the
antibody in heavy and light chains.
Gel pieces containing the crosslinked complexes were washed with 25 mM ammonium bicarbonate (pH 7.8) for 1 h with shaking.
The solution was removed and the pieces destained three times with 25 mM ammonium bicarbonate in 60% acetonitrile. Gel pieces
were dehydrated with 100% acetonitrile for 10 min and left to air-dry in a laminar flowhood for 1 h. Rehydration of the gel pieces was
achieved by adding 0.1 mg/mL trypsin solution and incubating the samples on ice for 30 min. Excess trypsin was removed and the
samples were incubated at 37Cand 1000 rpmovernight. Peptideswere extracted from the gel using 3washeswith 60%acetonitrile/
5% formic acid. The extracts were pooled and concentrated using a SpeedVac before being analyzed using a nanoACQUITY LC-
system coupled to a Synapt HDMS G2Si mass spectrometer. Peptides were injected onto a C18 column equilibrated with 0.1% for-
mic acid inwater and eluted using an increasing gradient of 0.1% formic acid in acetonitrile over 60min at a flow rate of 0.3 ml/min. The
Synapt HDMS G2Si was operated in positive mode using a capillary voltage of 3.0 kV, cone voltage of 40 V, backing pressure of 3.6
mbar and a trap bias of 2.0 V. The source temperature was 80C and the trap pressure was 8.70 3 103 mBar. Glu-fibrinogen and
Leucine Enkephalin were infused as lockmass calibrants. Data acquisitionwas achieved usingData Dependent Analysis (DDA) with a
one secondMS scan over anm/z range of 250–3000 being followed by three 1 sMS/MS scans taken from the fivemost intense ions in
the MS spectrum over anm/z range of 50–2000. Data processing was performed using the MassLynx v4.1 suite of software supplied
with the mass spectrometer and PEAKS 7/8 (Bioinformatics Solutions). Crosslinks were identified using StavroX software (Go¨tze
et al., 2012) and verified manually.
Luciferase refolding assay
Firefly Luciferase refolding activity was measured as previously described (Sun et al., 2012). Recombinant luciferase (2.5 mM) was
chemically denatured for 45 min at room temperature in denaturing buffer (25 mM HEPES/KOH, pH 7.4, 50 mM KCl,
15 mM MgCl2, 1 mM ATP, 10 mM DTT, 0.05 mg/mL BSA, 5 M GdmCl). To test for refolding activity, 0.02 mM denatured luciferase
was preincubated in the presence or absence of 0.02 mM NAC variants for 15 min at room temperature. Luciferase refolding was
induced by addition of 3.2 mM CeHsc70 (HSP-1), 0.8 mM CeHsp40 (DNJ-13) and luminescence buffer (75 mM HEPES/KOH, pH
7.4, 50 mM KCl, 15 mM MgCl2, 1 mM ATP, 2 mM DTT, 0.05 mg/mL BSA, 240 mM Coenzyme A, 0.1 mM luciferin, 10 mM PEP,
50 mg/mL pyruvate kinase). Luminescence wasmeasured in 96-well LIA-plates (Greiner) over 2 hours at room temperature in amicro-
plate reader (BertholdTech TriStar2S).e5 Molecular Cell 74, 729–741.e1–e7, May 16, 2019
C. elegans transformation
Transgenic strains were generated using standard microinjection protocols (Mello and Fire, 1995). Constructs for overexpression of
NAC in bodywall muscles were generated by cloning the coding sequences of icd-1 (bNAC) and icd-2 (aNAC) into pPD61_125 vector
containing themyo-3 promoter and the unc-54 30 untranslated region (UTR). The NAC genes were N-terminally tagged with 3x FLAG.
Mutant NAC constructs were generated by standard mutagenesis protocols. AM140 (rmIs132 [unc-54p::Q35::YFP]) and FlucDM-
EGFP (marIs135 [unc-54p::FlucDM::EGFP]) worms were injected with 25 ng/ml of each NAC plasmid together with CFJ90 myo-2p::
mCherry (2.5 ng/ml) (Frøkjaer-Jensen et al., 2008) andDNA ladder (100 ng/ml, GeneRuler 1 kb, Thermo Scientific). Control strains were
obtained by injecting 50 ng/ml empty vector, 2.5 ng/mlmyo-2p::mCherry and 100 ng/ml DNA ladder. For each transformation, at least
two independent transgenic lines carrying extrachromosomal arrays were obtained showing similar results. Detailed strain informa-
tion is available in Table S3.
Synchronization of C. elegans
Synchronization of worms for microscopic studies was carried out by a timed egg-lay for 5 h. Large age-synchronized C. elegans
cultures for SDD-AGE analyses were obtained by collecting embryos from gravid adult worms using a 20% alkaline hypochlorite
bleaching for 5 min. Embryos were allowed to hatch overnight in M9 buffer to get arrested L1s. Transgenic L1 larvae were sorted
based on the myo-2p::mCherry marker using a COPAS FlowPilot system (Union Biometrica). The synchronized, transgenic L1s
were transferred to OP50 seeded plates and incubated at 20C. After two days the young adult wormswere transferred to new plates
containing 150 mM 5-fluorodeoxyuridine (LKT Laboratories) to prevent the culture from reproducing.
Fluorescence microscopy of worms
Worms were immobilized on 3% agarose pads and anaesthetized using 25 mM levamisole (LKT Laboratories). Images were taken
with a confocal laser-scanning microscope TCS SP8 (Leica) with 5x (whole body images) and 63x objectives (head region). Images
were adjusted as necessary in Fiji (ImageJ) (Schindelin et al., 2012) using cropping, brightness and contrast tools.
SDD-AGE
SDD-AGEwas carried out as previously described (Halfmann and Lindquist, 2008). For sample preparation, wormswere extracted in
lysis buffer (100 mM Tris-Cl pH 7.5, 50 mM NaCl, 10 mM b-mercaptoethenol, 1x complete protease inhibitor) by sonication (four
times, 10 pulses, duty cycle = 40, output control = 2; Branson sonifier). Lysed worms were centrifuged for 1 min at 500 g to remove
debris and the supernatant was transferred to a new tube. ¼ volume of 4x SDD-AGE sample buffer (2x TAE, 20% glycerol, 8% SDS,
0.05% bromphenol blue) was added to the lysates and incubated for 15 min at RT. Samples were loaded onto a 1.2% agarose gel in
1x TAE buffer (40 mM Tris-Cl, pH 7.6, 20 mM acetic acid, 1 mM EDTA) containing 0.1% SDS and proteins were blotted on nitrocel-
lulose membranes by capillary transfer in 1x Tris buffer (150 mM NaCl, 50 mM Tris-Cl pH 7.5) over night at room temperature. The
membrane was analyzed using an anti-GFP antibody (Covance).
Polysome analysis of worms
C. elegans N2 worms were cultivated in liquid culture at 20C in presence of E. coliOP50 as food source. Day 2 post-L4 worms were
harvested on ice with 0.1MNaCl and seperated from bacteria via sucrose floatation. After an additional washing step the nematodes
were flash frozen in liquid nitrogen. Worm pellets were cryo-genic grinded using a cryo-mill (Retsch) for 30 s at 22 Hz. Frozen worm
powder was resuspended in lysis buffer (30 mM HEPES/KOH pH 7.4, 50 mM KoAc, 5 mM MgCl2, 5% (w/v) mannitol, 100 mg/mL
cycloheximide, 2 mM b-mercaptoethanol, 1 x complete protease inhibitor) and centrifuged at 18,000 g for 15 min at 4C. The super-
natant was adjusted to 20 A260 U/mL and 500 ml were loaded on a sucrose gradient (15%–45% in lysis buffer). Ribosomal species
were separated by ultracentrifugation (TH-641 rotor) at 39,000 rpm for 2.5 hours (4C). Gradients were fractionated using a density
gradient fractionator (Teledyne Isco, Inc.) monitoring the A254 and fractions were directly analyzed by immunoblotting.
Paralysis assay
To analyze the percentage of paralyzed worms, 100 semi-synchronized (timed egg lay for 5 h) young adult worms of each strain were
placed on a plate containing 150 mM 5-fluorodeoxyuridine. Screening of paralyzed worms was started at day 6 of adulthood. Worms
were scored as paralyzed when they only moved their heads but failed to undergo a full body wave propagation upon repeated prod-
ding with a platinum wire worm picker.
Immunoblot analysis in C. elegans
Protein samples were applied to SDS–PAGE and electroblotted onto nitrocellulose membranes according to standard protocols.
Commercial antibodies used throughout this study were GFP (Covance, MMS-118P), FLAG (Sigma, F1804), Actin (Santa Cruz,
sc-47778), and uL16 (Abgent, AP176039). Polyclonal antibody against C. elegans NAC (aNAC + bNAC) was described previously
(Kirstein-Miles et al., 2013). Antibody against uL24 was raised in rabbits immunized with recombinant full-length C. elegans RPL-
26 protein. Tubulin antibodies were a kind gift from Thomas Mayer, University of Konstanz. Blots were probed with secondary
antibodies coupled to HRP (Jackson, anti-mouse 715-035-151; anti-rabbit 711-005-152).Molecular Cell 74, 729–741.e1–e7, May 16, 2019 e6
QUANTIFICATION AND STATISTICAL ANALYSIS
Experimental procedure
Each experiment was conducted at least three times to generate three biological repeats. For western blots, dot blots, and fluores-
cence microscope images the most representative experiment is shown.
Statistics
Bar graphs for quantifications show the average of at least three independent experiments ± SEM. Statistical parameters, including
the exact value of n and statistical significance are reported in the Figure Legends. Data are judged to be statistically significant when
p < 0.05 by the comparison test indicated in the Figure legends. In figures, asterisks denote statistical significance (*, p < 0.05, **,
p < 0.01, ***, p < 0.001) as compared to appropriate controls.
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